Medtox files drug screening test with FDA :
This article was originally published in Clinica
Executive Summary
Medtox Diagnostics, a subsidiary of Medtox Scientific, has submitted its PROFILE-ER drugs-of-abuse test to the US FDA for 510(k) marketing clearance. The product simultaneously detects nine of the most commonly used drugs-of-abuse - cocaine, amphetamines, cannabinoids, opiates, phencyclidine, benzodiazapine, barbiturate, tricyclic antidepressants and methadone. The test involves a one-step process and produces qualitative results in seven minutes, said St Paul, Minnesota-based Medtox. It will be targeted at hospital laboratories, emergency rooms and the urgent care market, allowing the end-user to perform an on-site screen for the drugs.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.